192 related articles for article (PubMed ID: 22895562)
1. Role of the angiogenic components, VEGFA, FGF2, OPN and RHOC, in urothelial cell carcinoma of the urinary bladder.
Zaravinos A; Volanis D; Lambrou GI; Delakas D; Spandidos DA
Oncol Rep; 2012 Oct; 28(4):1159-66. PubMed ID: 22895562
[TBL] [Abstract][Full Text] [Related]
2. Large-scale real-time reverse transcription-PCR approach of angiogenic pathways in human transitional cell carcinoma of the bladder: identification of VEGFA as a major independent prognostic marker.
Pignot G; Bieche I; Vacher S; Güet C; Vieillefond A; Debré B; Lidereau R; Amsellem-Ouazana D
Eur Urol; 2009 Oct; 56(4):678-88. PubMed ID: 18513850
[TBL] [Abstract][Full Text] [Related]
3. DDR2 overexpression in urothelial carcinoma indicates an unfavorable prognosis: a large cohort study.
Tsai MC; Li WM; Huang CN; Ke HL; Li CC; Yeh HC; Chan TC; Liang PI; Yeh BW; Wu WJ; Lim SW; Li CF
Oncotarget; 2016 Nov; 7(48):78918-78931. PubMed ID: 27793038
[TBL] [Abstract][Full Text] [Related]
4. Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer.
Kamai T; Tsujii T; Arai K; Takagi K; Asami H; Ito Y; Oshima H
Clin Cancer Res; 2003 Jul; 9(7):2632-41. PubMed ID: 12855641
[TBL] [Abstract][Full Text] [Related]
5. The role of RhoC in ovarian epithelial carcinoma: a marker for carcinogenesis, progression, prognosis, and target therapy.
Zhao Y; Zheng HC; Chen S; Gou WF; Xiao LJ; Niu ZF
Gynecol Oncol; 2013 Sep; 130(3):570-8. PubMed ID: 23764197
[TBL] [Abstract][Full Text] [Related]
6. RhoC, vascular endothelial growth factor and microvascular density in esophageal squamous cell carcinoma.
Zhao ZH; Tian Y; Yang JP; Zhou J; Chen KS
World J Gastroenterol; 2015 Jan; 21(3):905-12. PubMed ID: 25624724
[TBL] [Abstract][Full Text] [Related]
7. [Expressions of RhoC and osteopontin in esophageal squamous carcinoma and association with the patients' prognosis].
Zhang HZ; Liu JG; Wei YP; Wu C; Cao YK; Wang M
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Nov; 26(11):1612-5. PubMed ID: 17121713
[TBL] [Abstract][Full Text] [Related]
8. Expression profile of Rho kinases in urinary bladder cancer.
Volanis D; Zaravinos A; Kadiyska T; Delakas D; Zoumpourlis V; Spandidos DA
J BUON; 2011; 16(3):511-21. PubMed ID: 22006759
[TBL] [Abstract][Full Text] [Related]
9. Osteopontin overexpression predicts poor prognosis of upper urinary tract urothelial carcinoma.
Ke HL; Chang LL; Yang SF; Lin HH; Li CC; Wu DC; Wu WJ
Urol Oncol; 2011; 29(6):703-9. PubMed ID: 20022267
[TBL] [Abstract][Full Text] [Related]
10. B7-H4 expression is correlated with tumor progression and clinical outcome in urothelial cell carcinoma.
Fan M; Zhuang Q; Chen Y; Ding T; Yao H; Chen L; He X; Xu X
Int J Clin Exp Pathol; 2014; 7(10):6768-75. PubMed ID: 25400757
[TBL] [Abstract][Full Text] [Related]
11. GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator.
Inoue S; Mizushima T; Fujita K; Meliti A; Ide H; Yamaguchi S; Fushimi H; Netto GJ; Nonomura N; Miyamoto H
Hum Pathol; 2017 Jun; 64():83-90. PubMed ID: 28428106
[TBL] [Abstract][Full Text] [Related]
12. RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells.
van Golen KL; Wu ZF; Qiao XT; Bao L; Merajver SD
Neoplasia; 2000; 2(5):418-25. PubMed ID: 11191108
[TBL] [Abstract][Full Text] [Related]
13. Expression analysis of VEGF-A and VEGF-B: relationship with clinicopathological parameters in bladder cancer.
Fauconnet S; Bernardini S; Lascombe I; Boiteux G; Clairotte A; Monnien F; Chabannes E; Bittard H
Oncol Rep; 2009 Jun; 21(6):1495-504. PubMed ID: 19424629
[TBL] [Abstract][Full Text] [Related]
14. RhoC is a major target of microRNA-93-5P in epithelial ovarian carcinoma tumorigenesis and progression.
Chen X; Chen S; Xiu YL; Sun KX; Zong ZH; Zhao Y
Mol Cancer; 2015 Feb; 14(1):31. PubMed ID: 25649143
[TBL] [Abstract][Full Text] [Related]
15. Expression of miRNA-630 in bladder urothelial carcinoma and its clinical significance.
Wang ZY; Zhang W; Yang JJ; Song DK; Wei JX
J Huazhong Univ Sci Technolog Med Sci; 2016 Oct; 36(5):705-709. PubMed ID: 27752905
[TBL] [Abstract][Full Text] [Related]
16. Expression and function analysis of indoleamine 2 and 3-dioxygenase in bladder urothelial carcinoma.
Yang C; Zhou Y; Zhang L; Jin C; Li M; Ye L
Int J Clin Exp Pathol; 2015; 8(2):1768-75. PubMed ID: 25973066
[TBL] [Abstract][Full Text] [Related]
17. Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.
Eltze E; Wild PJ; Wülfing C; Zwarthoff EC; Burger M; Stoehr R; Korsching E; Hartmann A
Eur Urol; 2009 Nov; 56(5):837-45. PubMed ID: 18945538
[TBL] [Abstract][Full Text] [Related]
18. High NF-κB and STAT3 activity in human urothelial carcinoma: a pilot study.
Degoricija M; Situm M; Korać J; Miljković A; Matić K; Paradžik M; Marinović Terzić I; Jerončić A; Tomić S; Terzić J
World J Urol; 2014 Dec; 32(6):1469-75. PubMed ID: 24448750
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling in bladder cancer identifies potential therapeutic targets.
Hussain SA; Palmer DH; Syn WK; Sacco JJ; Greensmith RMD; Elmetwali T; Aachi V; Lloyd BH; Jithesh PV; Arrand J; Barton D; Ansari J; Sibson DR; James ND
Int J Oncol; 2017 Apr; 50(4):1147-1159. PubMed ID: 28259975
[TBL] [Abstract][Full Text] [Related]
20. GPX2 underexpression indicates poor prognosis in patients with urothelial carcinomas of the upper urinary tract and urinary bladder.
Chang IW; Lin VC; Hung CH; Wang HP; Lin YY; Wu WJ; Huang CN; Li CC; Li WM; Wu JY; Li CF
World J Urol; 2015 Nov; 33(11):1777-89. PubMed ID: 25813210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
